Navigation Links
Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
Date:3/6/2013

60; A history of the organization, upcoming events, and a list of programs receiving funding from the Colon Cancer Coalition can be found at GetYourRearinGear.com.

About Sanofi Oncology

At Sanofi Oncology, the patient is our inspiration. We are dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Through our global organization of talented and passionate employees, we are building a renewed and diversified portfolio, driven by the principles of innovation, personalization and patient access to medicines. We believe that delivering innovative treatment solutions requires collaboration with external experts, which is why we partner our own internal expertise with the best experts in scientific discovery and clinical research around the world.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements.  Forward-looking statements are statements that are not historical facts.  These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.  Forward-looking statements are generally identified by the words "expects", "anticipates"
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
7. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... appointed Francois Vieillard as Sales & Marketing Director. , With more than ... will be responsible for reinforcing Tronics’ business development activities worldwide. He brings to ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 10, 2012  Spherix Incorporated (NASDAQ: SPEX ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – would like ... will host a conference call to provide a ...
... Florida have developed a novel technique that may give ... pathogens associated with inflammatory bowel disease, including Crohn,s disease. ... used for detection of other microbes that have challenged ... tissue and are able to reprogram cells to successfully ...
... Syndax Pharmaceuticals, Inc. , a clinical-stage epigenetics oncology ... Texas MD Anderson Cancer Center Department of Breast ... combining Syndax,s lead product entinostat with lapatinib ditosylate ... relapsed metastatic breast cancer previously treated with trastuzumab ...
Cached Biology Technology:Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 2Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time 3UCF scientists use nanotechnology to hunt for hidden pathogens 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 2Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer 3
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... led by Lauren Cole, a public health graduate student, ... and Director of the Epidemiology Program at LSU Health ... head and neck cancer has risen at sites associated ... increase among middle-aged white men. At the same time, ...
... developed a new method to detect proteins associated with longevity, ... longer than others. The team looked at the genome ... evolve in connection with the longevity of a species. ... damage, evolves and mutates in a non-random way in species ...
... This press release is available in German . ... a complex process during which different signalling proteins interact with ... VEGF and the Notch signalling pathway both play important roles ... its receptor, VEGFR2, while the Notch signalling pathway acts like ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2Study suggests why some animals live longer 2Culprit behind unchecked angiogenesis identified 2
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Request Info...
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: